Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




READERS COMMENTS:

Pfizer, Medivation Nix Development of Alzheimer Disease Therapy
Back to Item

Second Phase III study failing to meet its endpoints prompted firms to end partnership.

1 Readers' Comments

Post a Comment

Posted by: Eric Starson

01/18/2012

I was fascinated to discover that there's been research on saffron versus Aricept (donepezil). Check it out: http://nutritionfacts.org/videos/saffron-versus-aricept/. (noncommercial, science-based site)  According to the findings, saffron works just as well (which isn't all that well, though better than placebo). And without the side effects.

Click here to log in or to register for free.

You will be taken back to your selected item after log-in/registration.

Subscription center

BACK TO TOP

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.
 

All fields are required
Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

GEN webinars

« View All Webinars »

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll
« More »     « View Results »     « Poll Archive »